Parvovirus B19 infection and kidney injury: report of 4 cases and analysis of immunization and viremia in an adult cohort of 100 patients undergoing a kidney biopsy.


Journal

BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793

Informations de publication

Date de publication:
09 07 2020
Historique:
received: 07 06 2019
accepted: 25 06 2020
entrez: 11 7 2020
pubmed: 11 7 2020
medline: 14 10 2021
Statut: epublish

Résumé

The seroprevalence of human Parvovirus B19 (PVB19) is 70-85% in adults worldwide. PVB19 is the etiologic agent of the fifth disease, is a cause of aplastic anemia, and can be associated with kidney injury. We aimed to describe the cases of 4 patients with kidney injury related to PVB19 primary infection, and to evaluate the seroprevalence of PVB19 and the incidence of PVB19 primary infection in patients undergoing a native kidney biopsy. Cases of PVB19 infection with kidney injury were reviewed from the archives of the department of Nephrology. A systematic screening of anti-PVB19 IgG and IgM antibodies and viral DNA was performed in sera from 100 consecutive patients with a kidney biopsy in 2017-2018. The 4 patients with PVB19 infection-associated kidney disease displayed: one lupus-like glomerulonephritis (GN) without lupus auto-antibodies, one minimal change disease with tubular necrosis, one secondary hemolytic and uremic syndrome and one membrano-proliferative GN. In the 100 patients biopsied, 67 had elevated anti-PVB19 IgG, among whom 8 had elevated IgM, without circulating viral DNA, without any particular renal pathological pattern. One additional patient showed a seroconversion at the time of kidney biopsy, which revealed a class V lupus nephritis. PVB19 primary infection can be associated with different kidney diseases. The seroprevalence of PVB19 among patients with a kidney biopsy is similar to the overall population, and primary infection is rarely documented (1%) after systematic screening. Whether PV19 is nephrotoxic, or triggers renal endothelial injury and immune activation, remains to be elucidated.

Sections du résumé

BACKGROUND
The seroprevalence of human Parvovirus B19 (PVB19) is 70-85% in adults worldwide. PVB19 is the etiologic agent of the fifth disease, is a cause of aplastic anemia, and can be associated with kidney injury. We aimed to describe the cases of 4 patients with kidney injury related to PVB19 primary infection, and to evaluate the seroprevalence of PVB19 and the incidence of PVB19 primary infection in patients undergoing a native kidney biopsy.
METHODS
Cases of PVB19 infection with kidney injury were reviewed from the archives of the department of Nephrology. A systematic screening of anti-PVB19 IgG and IgM antibodies and viral DNA was performed in sera from 100 consecutive patients with a kidney biopsy in 2017-2018.
RESULTS
The 4 patients with PVB19 infection-associated kidney disease displayed: one lupus-like glomerulonephritis (GN) without lupus auto-antibodies, one minimal change disease with tubular necrosis, one secondary hemolytic and uremic syndrome and one membrano-proliferative GN. In the 100 patients biopsied, 67 had elevated anti-PVB19 IgG, among whom 8 had elevated IgM, without circulating viral DNA, without any particular renal pathological pattern. One additional patient showed a seroconversion at the time of kidney biopsy, which revealed a class V lupus nephritis.
CONCLUSION
PVB19 primary infection can be associated with different kidney diseases. The seroprevalence of PVB19 among patients with a kidney biopsy is similar to the overall population, and primary infection is rarely documented (1%) after systematic screening. Whether PV19 is nephrotoxic, or triggers renal endothelial injury and immune activation, remains to be elucidated.

Identifiants

pubmed: 32646497
doi: 10.1186/s12882-020-01911-9
pii: 10.1186/s12882-020-01911-9
pmc: PMC7350584
doi:

Substances chimiques

Antibodies, Viral 0
DNA, Viral 0
Immunoglobulin G 0
Immunoglobulin M 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

260

Références

J Autoimmun. 2015 Dec;65:74-81
pubmed: 26320984
J Clin Microbiol. 1986 Oct;24(4):522-6
pubmed: 3021807
FASEB J. 1992 Feb 1;6(3):840-4
pubmed: 1740233
Epidemiol Infect. 2007 Nov;135(8):1354-62
pubmed: 17291377
Am J Kidney Dis. 2000 Jun;35(6):E31
pubmed: 10845847
Nephrol Ther. 2012 Feb;8(1):5-12
pubmed: 21757415
Clin Microbiol Rev. 2002 Jul;15(3):485-505
pubmed: 12097253
Clin Diagn Virol. 1997 Feb;7(3):133-7
pubmed: 9126681
Rev Med Interne. 2014 May;35(5):289-96
pubmed: 23773900
Nephron. 2001 Nov;89(3):280-5
pubmed: 11598390
Clin Infect Dis. 2010 Apr 1;50(7):1074-5
pubmed: 20201675
J Med Virol. 1991 Oct;35(2):110-5
pubmed: 1765775
Clin J Am Soc Nephrol. 2007 Jul;2 Suppl 1:S47-56
pubmed: 17699510
Am J Med. 2015 Sep;128(9):950-5
pubmed: 25837517
Clin Rheumatol. 2008 Jan;27(1):119-20
pubmed: 17622480
Clin Infect Dis. 2013 Apr;56(7):968-77
pubmed: 23243178
Transfusion. 2008 Jan;48(1):178-86
pubmed: 17900278
Kidney Int. 2001 Jun;59(6):2126-33
pubmed: 11380814
Epidemiol Infect. 2000 Jun;124(3):449-57
pubmed: 10982069
Joint Bone Spine. 2018 Jan;85(1):129-130
pubmed: 28062379
J Virol. 2014 Jul;88(14):8102-15
pubmed: 24807719
J Med Microbiol. 1988 Feb;25(2):151-3
pubmed: 3339634
Am J Kidney Dis. 2000 Jun;35(6):1166-74
pubmed: 10845832
J Rheumatol. 2002 Jun;29(6):1227-35
pubmed: 12064841
BMC Nephrol. 2016 Sep 06;17(1):125
pubmed: 27600725
Cell Biochem Funct. 2007 Nov-Dec;25(6):639-41
pubmed: 16917962
J Virol Methods. 2001 Apr;92(2):183-91
pubmed: 11226565
Epidemiol Infect. 2008 Nov;136(11):1564-75
pubmed: 18198003
Autoimmun Rev. 2007 Apr;6(5):278-85
pubmed: 17412298
BMJ Case Rep. 2016 Jan 25;2016:
pubmed: 26811413
J Infect Dis. 2019 Apr 16;219(9):1418-1429
pubmed: 30346568
CMAJ. 2005 Mar 15;172(6):743
pubmed: 15767606
Pathol Biol (Paris). 2002 Jun;50(5):307-16
pubmed: 12116849
Ann Rheum Dis. 2005 Apr;64(4):641-3
pubmed: 15485998
Acta Clin Belg. 2016 Dec;71(6):423-425
pubmed: 27075795
Clin Nephrol. 2016 Apr;85(4):238-44
pubmed: 26833301

Auteurs

Maëlis Kauffmann (M)

AP-HM, Department of Nephrology, Hopital de la Conception, Marseille, France.

Mickaël Bobot (M)

AP-HM, Department of Nephrology, Hopital de la Conception, Marseille, France.
Aix-Marseille Univ, C2VN, INSERM 1263, INRA 1260, Campus Timone, Marseille, France.

Laurent Daniel (L)

Aix-Marseille Univ, C2VN, INSERM 1263, INRA 1260, Campus Timone, Marseille, France.
AP-HM, Laboratory of Pathology, Hopital de la Timone, Marseille, France.

Julia Torrents (J)

AP-HM, Laboratory of Pathology, Hopital de la Timone, Marseille, France.

Yannick Knefati (Y)

Department of Nephrology, Hôpital Sainte Musse, Toulon, France.

Olivier Moranne (O)

Department of Nephrology, CHU de Nîmes, Nîmes, France.

Stéphane Burtey (S)

AP-HM, Department of Nephrology, Hopital de la Conception, Marseille, France.
Aix-Marseille Univ, C2VN, INSERM 1263, INRA 1260, Campus Timone, Marseille, France.

Christine Zandotti (C)

UVE, Aix-Marseille Univ, IRD 190, Inserm 1207, IHU Méditerranée Infection and AP-HM, Marseille, France.

Noémie Jourde-Chiche (N)

AP-HM, Department of Nephrology, Hopital de la Conception, Marseille, France. noemie.jourde@ap-hm.fr.
Aix-Marseille Univ, C2VN, INSERM 1263, INRA 1260, Campus Timone, Marseille, France. noemie.jourde@ap-hm.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH